BridgeBio Oncology Shares Soar 26% Amid SPAC Merger and RAS-Targeted Breakthroughs

Introduction

BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Established in May 2024 as a spin-out from BridgeBio Pharma, BBOT focuses on small-molecule therapeutics targeting cancers driven by aberrant RAS signaling and PI3Kα activation.

Corporate structure

BBOT employs between 51 and 200 staff, which includes RAS cancer biologists, medicinal chemists, and drug developers. Leadership comprises CEO Eli Wallace, PhD, and CSO Pedro J. Beltran, PhD. The Board of Directors is chaired by Frank McCormick, PhD, and includes Raymond Kelleher, MD, PhD; Michelle Doig; and Neil Kumar, PhD. The company completed a $200 million private financing in May 2024 and is set to merge with Helix Acquisition Corp. in the third quarter of 2025, at which point it will begin trading on Nasdaq under the ticker “BBOT.”

Oncology by Angiola Harry

Recent developments and news

• May 2, 2024: BBOT launched with $200 million in private external capital, led by Cormorant Asset Management and co-led by Omega Funds.
• Q2 2024: An Investigational New Drug (IND) application was filed for BBO-10203, a RAS:PI3Kα breaker. Patient enrollment began later in 2024.
• Early 2025: Planned IND filing for BBO-11818, a pan-KRAS inhibitor targeting multiple KRAS-mutant proteins.
• November 13–14, 2025: Amendments to Schedule 13G/A filings disclosed that Citadel entities held shared voting and dispositive power over 1,487,621 shares (1.88%) and 2,528,762 shares (3.2%) as of September 30, 2025.
• December 5, 2025: BBOT closed at $14.555, reflecting an increase of 26.13% on a volume of 155,823 shares.

Clinical pipeline highlights:

• BBO-8520: Direct KRAS G12C inhibitor in the ONKORAS-101 Phase 1 trial for non-small cell lung cancer.
• BBO-10203: RAS:PI3Kα breaker in the Phase 1 BREAKER-101 trial for breast, colorectal, and lung cancers; initial data is expected in the first half of 2026.
• BBO-11818: Pan-KRAS inhibitor advancing toward an IND filing.

BBOT leadership presented at the Piper Sandler and Evercore Healthcare Conferences in December 2025, and will feature poster sessions at the San Antonio Breast Cancer Symposium and data presentations at the AACR-NCI-EORTC Molecular Targets & Cancer Therapeutics Conference.

Financial and strategic analysis

As of December 5, 2025, BBOT’s market capitalization stood at approximately $1.16 billion, based on 79.99 million shares outstanding. The 52-week trading range is $8.50–$14.78. Key metrics include:

• EPS (TTM): $0.20
• P/E ratio (TTM): 71.78
• EBITDA (TTM): –$3.908 million
• ROE (TTM): 2.53%

Following the SPAC merger, the company is projected to hold roughly $550 million in cash and equivalents, which would fund multiple clinical and discovery programs through key inflection points. BBOT’s strategy emphasizes drug design informed by RAS biology to deliver oncology candidates with efficacy and safety profiles.

Market position and industry context

BBOT operates in the RAS-driven oncology segment, which represents about 25% of all human tumors. Key competitors include Amgen and Bristol Myers Squibb, each with KRAS G12C inhibitors. BBOT aims to address resistance mechanisms and reduce adverse effects by targeting both “on” and “off” states of KRAS and selectively disrupting RAS-PI3Kα interactions. The use of the SPAC route is consistent with current market trends favoring alternative public listings for biotech companies.

tl;dr

On December 5, 2025, BBOT shares increased by 26.13% to $14.555. The company is actively enrolling patients in its BBO-8520 and BBO-10203 trials, with initial Phase 1 data for the PI3Kα breaker expected in the first half of 2026. A planned SPAC merger in Q3 2025 will secure approximately $550 million in capital. Institutional ownership disclosures as of September 30, 2025, indicate Citadel entities holding over 3% of shares, reflecting investor interest in BBOT’s precision oncology pipeline.